Elisabeth Bendstrup

Autoimmune pulmonary alveolar proteinosis in an adolescent successfully treated with inhaled rhGM-CSF (molgramostim)

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare parenchymal lung disease characterized by accumulation of surfactant in the airways with high levels of granulocyte-macrophage colony stimulating factor (GM-CSF) antibodies in blood. Disease leads to hypoxemic respiratory failure. Whole lung lavage (WLL) is considered the first line therapy, but procedure can be quite demanding, specifically for children. Recently alternative treatment options with inhaled GM-CSF have been described but no consensus about the standard treatment exists. We here describe a unique case of a 14-year-old patient who was successfully treated with WLL and subsequent inhalations with molgramostim – new recombinant human GM-CSF (rhGM-CSF).

Original languageEnglish
JournalRespiratory medicine case reports
Pages (from-to)167-169
Number of pages3
Publication statusPublished - 1 Jan 2018

    Research areas

  • GM-SCF, Granulocyte-macrophage colony-stimulating factor, Inhalation therapy, Molgramostim, Pulmonary alveolar proteinosis

See relations at Aarhus University Citationformats

ID: 148606417